Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 8/20 | 0.35 |
| ▸ | CA2 | P00918 | 6/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 6/20 | 0.33 |
| ▸ | CA9 | Q16790 | 5/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21798007 | 0.72 | LMNA (0.33) | — | |
| Hydrochloric Acid SCHEMBL21798240 | 0.71 | — | — | |
| SCHEMBL18866772 | 0.70 | HCRTR2 (0.41) | HCRTR2CA12CA2CA14TDP1 | |
| SCHEMBL15497077 | 0.69 | HCRTR2 (0.43) | HCRTR2CA12CA2CA14TDP1 | |
| SCHEMBL13641704 | 0.69 | HCRTR2 (0.48) | HCRTR2CA12CA2CA14TDP1 | |
| SCHEMBL15497076 | 0.69 | HCRTR2 (0.44) | HCRTR2CA12CA2TDP1MEN1 | |
| SCHEMBL21798133 | 0.68 | — | — | |
| SCHEMBL8253836 | 0.68 | HCRTR2 (0.42) | HCRTR2CA12CA2TDP1MEN1 | |
| SCHEMBL14351298 | 0.68 | TDP1 (0.45) | HCRTR2CA12CA2CA14TDP1 | |
| SCHEMBL21798404 | 0.68 | CYP3A4 (0.34) | MEN1KMT2AGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230052629-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-02-16 | — | — | US | disclosed |
| US-11072610-B2 | Antiviral pyridopyrazinedione compounds | NOVARTIS AG (CH) | 2021-07-27 | — | — | US | disclosed |
| CN-112996789-A | Antiviral pyridopyrazinedione compounds | 诺华股份有限公司 | 2021-06-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230052629-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | ZC3HAV1, IL5, TYMP | HCRTR2 3981/4885CA12 4253/4885CA2 3139/4885 |
| US-11072610-B2 | Antiviral pyridopyrazinedione compounds | ZC3HAV1, IL5, TYMP | HCRTR2 3981/4885CA12 4253/4885CA2 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.